This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Talaporfin
- DrugBank Accession Number
- DB11812
- Background
Talaporfin has been investigated for the treatment of Port-Wine Stain and Benign Prostatic Hyperplasia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Talaporfin (DB11812)
- Weight
- Average: 711.772
Monoisotopic: 711.29042792 - Chemical Formula
- C38H41N5O9
- Synonyms
- Talaporfin
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareArticaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Talaporfin is combined with Cocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Talaporfin Sodium L63605PZ70 220201-34-3 KPALSRNVSRWOPA-YJFNSWLASA-J
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P4ROX5ELT2
- CAS number
- 110230-98-3
- InChI Key
- VSEIDZLLWQQJGK-WSUYNKMOSA-N
- InChI
- InChI=1S/C38H41N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-32(45)46)35(42-26)23(11-31(44)41-30(37(49)50)15-33(47)48)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,30,39,43H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,26-12-,27-14-,28-13-,29-14-,35-23-,36-23-/t18-,22-,30-/m0/s1
- IUPAC Name
- (2S)-2-{2-[(4S,5S)-20-carboxy-4-(2-carboxyethyl)-10-ethenyl-15-ethyl-5,9,14,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1,3(24),6,8,10,12,14,16(22),17,19-decaen-2-yl]acetamido}butanedioic acid
- SMILES
- CCC1=C(C)\C2=C\C3=C(C=C)C(C)=C(N3)\C=C3/N=C([C@@H](CCC(O)=O)[C@@H]3C)/C(/CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C3\N\C(=C/C1=N2)C(C)=C3C(O)=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5486799
- PubChem Substance
- 347828159
- ChemSpider
- 16737134
- ChEBI
- 135875
- ChEMBL
- CHEMBL2111186
- Wikipedia
- Talaporfin
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Colorectal Neoplasms / Metastatic Cancer / Metastatic Cancer to Liver / Recurrence, Local Neoplasm 1 3 Completed Treatment Hepatocellular Carcinoma / Neoplasms, Hepatic 1 2 Completed Treatment Anaplastic Astrocytoma (AA) / Glioblastoma Multiforme (GBM) / Glioma 1 2 Completed Treatment Benign Prostatic Hyperplasia (BPH) 1 2 Completed Treatment Benign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS) 1 2 Completed Treatment Colorectal Neoplasms / Metastatic Cancer / Metastatic Cancer to Liver / Neoplasms, Hepatic 2 1 Completed Treatment Benign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Symptoms (LUTS) 1 1 Completed Treatment Port-wine Stains (PWS) 1 1 Terminated Treatment Macular Degeneration / Subfoveal Choroidal Neovascularization (CNV) 1 1 Terminated Treatment Neurofibromas 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00797 mg/mL ALOGPS logP 2.23 ALOGPS logP 2.58 Chemaxon logS -5 ALOGPS pKa (Strongest Acidic) 2.79 Chemaxon pKa (Strongest Basic) 5.45 Chemaxon Physiological Charge -4 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 235.66 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 189.23 m3·mol-1 Chemaxon Polarizability 76.96 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at October 20, 2016 20:50 / Updated at February 21, 2021 18:53